MoonLake Immunotherapeutics Advances Key Trials with Strong Cash Reserves MoonLake Immunotherapeutics has initiated three new clinical trials for its lead drug candidate, sonelokimab, targeting inflammatory conditions such as hidradenitis suppurativa and psoriatic arthritis. With $448 million in cash reserves, the company is financially positioned to sustain operations through 2026, aiming to release pivotal trial data by mid-2025.12